AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05302154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction by virtual reality glasses
Description: During the treatment visual and auditory stimuli provide information about treatment to the patient with the help of avatars (characters) and environmental elements placed within the VRG application. In a vivid dentist room, the explanatory introduction part takes place while the movies are watched in a fairy world or a futuristic world to separate the user from the actual location and context. The application was designed to function in such a way as not to require outside intervention. From start to finish, the application interacts with the user through gaze selection and head tracking mechanisms. The avatar characters provide information related to the dental treatment in a joyful manner. Gamification elements such as gaining stars and collecting rewards have been used to keep the patient engaged. Motion blur feature ensures the patient to keep head still as sudden movements are dangerous and undesired by the dentist during the treatment.
Study NCT05698147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor dose escalation: 60,80,100mg respectively on day 1,8,15,22 for 28 days cycles, and dose expansion at the RP2D of Selinexor.~PR patients after induction treatment will continue ATG-010 maintenance up to 1 year or until disease progression, intolerable toxicity, death.
Study NCT05698147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Study NCT05698147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Study NCT05608044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
Study NCT05608044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
Study NCT05608044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Regorafenib or trifluridine and tipiracil.
Study NCT04852458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) hydrocortisone
Description: Participants (20) will be given IV hydrocortisone within 6-12 hours of the traumatic event.~90 - 150 mg. of intravenous hydrocortisone dosing regimen based on participant weight: 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
Study NCT06523504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIMS
Description: wear DIMS ,and use placebo,once nightly, both eye
Study NCT06523504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The 0.02% ATP Group
Description: wear SP, and use 0.02%ATP eye drops, once nightly, both eye
Study NCT06523504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The 0.04% ATP Group
Description: wear SP, and use 0.04%ATP eye drops, once nightly, both eye
Study NCT06523504 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.02%ATP+DIMS
Description: wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye
Study NCT06523504 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.04%ATP+DIMS
Description: wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye
Study NCT06391736 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GC301
Description: GC301, is an adeno-associated virus 9 (AAV9) vector delivering a functional copy of the human GAA gene
Study NCT05041296 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance scan
Description: Multiparametric cardiac magnetic resonance including traditional and quantitative functional and structural parameters
Study NCT05011864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: In BA, depressive symptoms are viewed as depressive behaviors. Compared to those without depression, people with depression engage in fewer overt behaviors that provide positive reinforcement and pleasure/enjoyment and in more behaviors that function to escape or avoid aversive stimuli (e.g., staying in bed all day).55-59 Thus, BA is aimed at increasing and reinforcing meaningful, healthy, and enjoyable behaviors while decreasing depressive behaviors and is well-suited to help depressed, disabled older adults increase mood-enhancing activities, self-care management skills, and social connectedness.
Study NCT05011864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall Prevention
Description: Following FP psychoeducation based on the Centers for Disease Control and Prevention (CDC)'s STEADI tool kits, lay coaches will assist clients in implementing evidence-based FP strategies that have been adapted for low-income homebound seniors. These include referrals to healthcare providers as needed, home safety checks, practice of safe ambulation/transfer and mobility aid use, medication review, and in-home exercise routines with an innovative, gamified tablet-based exercise app for balance and strength building.
Study NCT05011864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone support
Description: Subjects in this arm will receive 9 weekly support calls last 30 minutes each. These calls are intended to provide an opportunity for social support and check safety.
Study NCT04807387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Stent A
Description: Ring stent
Study NCT04807387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Stent B
Description: Flower stent
Study NCT04807387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Stent
Description: Vaginal stent chosen from A or B that is the most comfortable
Study NCT05104671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular stabilization exercises.
Description: General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:
Study NCT05104671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scapular stabilization exercises.
Description: General Instructions: For all exercises, perform the retraction of the scapula, without performing the elevation of the shoulders, taking the lower angle of the scapula back and down.~The exercise intensity was described as repetitions, sets, and holding time. Commonly, 10-20 repetitions and three to five sets held for 3-10 seconds were performed.and the exercises will be:~1. towel slide~2. Scapular Clock:~3. Scapular Proprioceptive Neuromuscular facilitation:~4. Inferior Glide.~5. Scapular Orientation Exercise (SOE):~6. Protraction and retraction in front of a mirror:
Study NCT05104671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation.
Description: • Thoracic Thrust Manipulation: The participants were in high sitting and in prone lying position. The therapist was standing next to the patient in a diagonal stance and also behind the patient during high sitting. Thoracic thrust manipulation demonstrated to manipulate specific thoracic segment mainly mid thoracic.
Study NCT05104671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release.
Description: The subject will be treated with IASTM.applied to the pectoral muscles and medial brachium with the subject in supine and the glenohumeral joint(GH). placed in 120 º abduction to place adequate tension on the selected tissues in the style of pectoral tightness test .The IASTM technique was performed for 20 seconds parallel to the muscle fibers followed by 20 seconds perpendicular to the muscle fibers with the instrument held at a 45 º angle to the skin.The same IASTM protocol of 20 seconds parallel to the muscle fibers and 20 seconds perpendicular to the muscle fibers was applied to the posterior cuff musculature of the GH joint with the subject in prone and arms in 90 º abduction and internal rotation draped over the side of the plinth . While in the same position, the technique was applied to the periscapular musculature including the, trapezoids, rhomboids, teres minor, teres major, and latissimus dorsi.
Study NCT05919485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC
Study NCT05919485 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: 0.06mA/cm2 from each electrode with total density of 0.054/cm2 for 20 minutes for 5 days a week, for 10 days and a total of 10 sessions in 14 days.~Brain area; DLPFC / LPC
Study NCT05245214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Muscle analysis by Magnetic Resonance Imaging
Study NCT05531435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
Study NCT05531435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Local anesthetic injection of articaine 4% + adrenaline 1/100.000 (Septanest, Septodont, Saint Maur des Fossés, France) with 30G - 9 mm needle (DENTAL HI TEC, ZI de l'Appentière, Mazières-en-Mauges, France).
Study NCT06415422 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples
Description: Biological samples are taken from the patient's catheter inserted upon admission (the usual access route for patients): A daily sample is collected into a dry tube for off-site analysis by VeriFyNow until platelet function normalizes (for example, if platelet function normalizes on Day 2, no further VeriFyNow analysis will be conducted on subsequent days).
Study NCT05048628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparıson
Description: Only evaluation will be made at 0, 4, 6, and 8 hours after surgery without intervention in the control group.~For other groups; Evaluation will be made at the 0th hour after the operation without application. The application will be made at the 4th, 6th, and 8th hours after the surgery and the resulting pain and hoarseness will be evaluated.
Study NCT01629420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109
Study NCT05831566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide/Formoterol fumarate dihydrate
Description: The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Study NCT05831566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol fumarate dihydrate
Description: The Digihaler will measure use of inhalation medication and inhaler technique and will give feedback and reminders. The aim is to improve adherence en inhaler technique. The device/medicinal product will be used for 12 months.~It will be used in both groups, but patients in the intervention group are not able to see their own results and will not receive feedback/reminders.
Study NCT05851898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg
Description: Duloxetine 30mg daily prescribed at discharge
Study NCT05477108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (BGF MDI HFO with oral activated charcoal)
Description: Subject will receive 4 inhalations as a single dose with oral activated charcoal - test formulation; administered during 1 Treatment Period.
Study NCT05928754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: care strategy
Description: Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.
Study NCT05928754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: care strategy
Description: Uveitis patients:~* Blood sample (20ml): Additional 20 ml blood sample during the first visit and potentially during follow-up (if necessary) for the purpose of the biological collection;~* Ocular sample (aqueous humor, vitreous): if required by the clinical context for the needs of the biological collection;~* Specific imaging: adaptive optics or Doppler holography, these procedures will be indicated on a case-by-case basis, at the investigator's discretion, and concern only patients with inflammatory vascular damage (5 to 10% of patients in the uveitis cohort);~* Quality of Life NEI-VFQ 25: provided at the inclusion visit and at follow-up visits M3-V2, M12-V5 and M24-V7.
Study NCT04927468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supramaximal rectus recession
Description: inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus
Study NCT04927468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normal rectus recession
Description: inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus
Study NCT05825404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Ambient Bright Light (SABL)
Description: The Proposed Smart Ambient Bright Light (SABL) includes tunable LED lights, photosensors, and controllers. The SABL will provide bright light targeted at 400 lux and CS=0.3 in participant bedrooms and designated areas such as the dining room and activity room during the day and provide dim light ≤40 lux and CS≤0.1 in participant bedrooms at night
Study NCT05825404 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Usual light.
Study NCT06273046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Three visits will be made throughout the study. The first visit (Day -14) will consist of an evaluation of the inclusion criteria. A pre-treatment anorectal manometry will be performed, and a daily symptom questionnaire will be given to the patient. The second visit will take place 14 days later (Day 0). During this visit, the daily clinical symptom questionnaire will be collected and it will be verified that the patient meets the inclusion criteria. Patients who meet the criteria will be randomized 2:1 to active treatment or placebo. Patients will receive instructions, by means of psychoeducational videos on the exercises to be performed daily at home. A final visit will be performed at the end of the study (3 months in incontinence studies and 4 weeks in dyssynergic defecation studies). In incontinence study a final phone call will be performed at 6 months.
Study NCT06273046 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three visits will be made throughout the study following the same procedure as patients in the active arm. Patients randomized to placebo treatment will receive instructions to take a pill of placebo containing 0.3 g glucose daily at home. A final visit will be performed at the end of the study alike the active treatment group.
Study NCT06104956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFNO weaning protocol
Description: Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
Study NCT06104956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Weaning methods will be left to the free choice of the practitioner.
Study NCT06507124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: This is observational with no intervention
Description: This is observational with no intervention
Study NCT05737719 — intervention group
Intervention type: BEHAVIORAL
Intervention: Rehabilitation before knee surgery (prehab)
Description: Physiotherapy strategies for preparing the patient awaiting the surgical procedure
Study NCT05737719 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post-surgery rehabilitation
Description: Physiotherapy strategies to manage post-surgery recovery
Study NCT05583994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optim Park Intervention
Description: For participants receiving the Optim-Park II intervention, the aim is to enhance the process of living with Parkinson's Disease for the person with PD and the family-carer by building a multisectoral care pathway, with a special focus on how to optimize the use of resources and systems of support in the community in disadvantaged populations in UK.
Study NCT06429189 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home-based combined exercise program with self-selected intensity
Description: Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
Study NCT06429189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based combined exercise program with self-selected intensity
Description: Before the beginning of the exercise program, participants will receive an education session on how to use Borg's Perceived Rate of Exertion Scale (RPE) to monitor their effort during aerobic and resistance training and tips on when they may increase the exercise intensity. During the training sessions, participants in the intervention group will be asked to choose their preferred load to execute each exercise in the resistance component, told to perform the aerobic exercises at their preferred speed, and informed that they can stop exercising whenever they need to rest. The exercise professional may suggest increasing loads in specific exercises, but these increases will not be imposed on the participants. Attendance to the sessions in the intervention and control groups will be registered. Additionally, women in this group will be encouraged to perform brisk walking at their preferred intensity and receive a pedometer to increase walking motivation.
Study NCT05477108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (BGF MDI HFA with oral activated charcoal)
Description: Subject will received 4 inhalations as a single dose with oral activated charcoal - reference formulation; administered during 2 Treatment Periods.
Study NCT06277089 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Casts
Description: According to level of scoliosis cast done and recast in a serial manner
Study NCT05069766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioXmark™
Description: During a scheduled outpatient gastroscopy, the tumor margins will be endoscopically marked by BioXmark™. BioXmark™ will be implanted at the most proximal margin of the tumor and 5 cm proximally of the tumor border.
Study NCT04877379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: β-lactamase inhibitor
Study NCT04877379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5024 (ceftibuten)
Description: β-lactam antibiotic
Study NCT04877379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05070065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive remedy intervention with virtual reality (CEREBRUM)
Description: Cognitive Remedial method Virtual Reality (CEREBRUM)
Study NCT05070065 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cognitive remedy intervention with virtual reality (CEREBRUM)
Description: Cognitive Remedial method Virtual Reality (CEREBRUM)